Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1024-1031

  Feldman, Adam S ^a   Banyard, Jacqueline ^c   Wu, Chin Lee ^a,b   McDougal, W Scott ^a   Zetter, Bruce R ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN B;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; TRANSITIONAL CELL CARCINOMA; URINALYSIS; WESTERN BLOTTING;

CARCINOMA, TRANSITIONAL CELL; CYSTATIN B; DISEASE PROGRESSION; HUMANS; PROTEIN ARRAY ANALYSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 61349115647     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1143     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71 -96.
2. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139: 283-5.
3. Althausen AF, Prout GR, Jr., Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
4. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60-1;discussion 1 -2.
5. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-96.
6. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54:215 -21.
7. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66: 64 - 74.
8. Kamai T, Takagi K, Asami H, ItoY, Oshima H, Yoshida KI. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84: 1242-51.
9. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000; 31:751 -60.
10. 1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999;36:393-400.
11. Lin CW, Lin JC, Prout GR, Jr. Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 1985;45:5070-9.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1967;50:163-70.
13. Katz MH. Multivariable analysis. A practical guide for clinicians. 2nd ed. New York: Cambridge University Press; 2006.
14. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991;285:213-9.
15. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer [review]. Oncol Rep 1998;5:1349-61.
16. Ebert E, Werle B, Julke B, et al. Expression of cysteine protease inhibitors stefin A, stefin B, cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997; 421:259-65.
17. Kastelic L, Turk B, Kopitar-Jerala N, et al. Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett 1994;82:81 -8.
18. Smid L, Strojan P, Budihna M, et al. Prognostic value of cathepsins B, D, steffins A and B in laryngeal carcinoma. Eur Arch Otorhinolaryngol 1997;254 Suppl 1:S150-3.
19. Lee MJ, Yu GR, Park SH, et al. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 2008;14:1080-9.
20. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000;6:505-11.
21. Strojan P, Budihna M, Smid L, et al. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2000;6:1052-62.
22. Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. J Urol 1995; 154:237-41.
23. Tokyol C, Koken T, Demirbas M, et al. Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori 2006;92:230-5.
24. Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 1997;15:368-81.
25. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995;55:5213-6.
26. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54: 784-8.
27. Millan-Rodriguez F, Chechile-Toniolo G, Salvador- Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
28. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001;165:600-11.
29. Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004; 50:857-66.
30. Gutierrez Banos JL, Rebollo Rodrigo MH, Antolin Juarez FM, Martin Garcia B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001;66:185-90.
31. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
32. Konety BR, Nguyen TS, Dhir R, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-25.
33. Van Le TS, Miller R, BarderT, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005;66:1256-60.
34. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-9.